• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

表面活性蛋白A可预测特发性肺纤维化患者的生存率。

Surfactant protein A predicts survival in idiopathic pulmonary fibrosis.

作者信息

McCormack F X, King T E, Bucher B L, Nielsen L, Mason R J

机构信息

Department of Medicine, National Jewish Center for Immunology and Respiratory Medicine, Denver, CO 80206, USA.

出版信息

Am J Respir Crit Care Med. 1995 Aug;152(2):751-9. doi: 10.1164/ajrccm.152.2.7633738.

DOI:10.1164/ajrccm.152.2.7633738
PMID:7633738
Abstract

The purpose of this study was to determine if the measurement of surfactant protein A (SP-A) in bronchoalveolar lavage (BAL) fluid predicts survival in patients with idiopathic pulmonary fibrosis (IPF). We performed BAL on 44 patients with IPF and 33 healthy volunteers. SP-A and total phospholipid (PL) were measured in the surfactant pelleted by centrifugation and expressed as a ratio to account for differences in the alveolar surface area sampled. The mean SP-A/PL was lower in patients with IPF than in healthy volunteers (31.8 +/- 2.8 versus 63.9 +/- 6.4 micrograms/mumol, p = 0.006) and in patients who died within 2 yr than in those who survived (23.4 +/- 2.6 versus 37.5 +/- 4.2 micrograms/mumol, p = 0.015). Using Cox's proportional hazard model, we found that SP-A/PL modeled continuously was associated with survival time (p = 0.002). The 5-yr survival of patients with SP-A/PL above the median level for all patients with IPF (29.7 micrograms/mumol) was more than twice that of patients below the median (68 versus 30%, p = 0.007). SP-A/PL improved upon prediction of survival modeled by most routine physiologic variables with the exception of percent predicted TLC or the multifarious clinical-radiographic-physiologic score (CRP). Cellular analysis of lavage did not predict survival in this cohort of patients. We conclude that SP-A/PL is a biochemical marker in lavage that predicts survival in patients with IPF.

摘要

本研究的目的是确定支气管肺泡灌洗(BAL)液中表面活性蛋白A(SP-A)的测量是否能预测特发性肺纤维化(IPF)患者的生存率。我们对44例IPF患者和33名健康志愿者进行了BAL。对通过离心沉淀的表面活性剂中的SP-A和总磷脂(PL)进行测量,并表示为一个比值,以考虑所采集肺泡表面积的差异。IPF患者的平均SP-A/PL低于健康志愿者(31.8±2.8对63.9±6.4微克/微摩尔,p = 0.006),在2年内死亡的患者低于存活患者(23.4±2.6对37.5±4.2微克/微摩尔,p = 0.015)。使用Cox比例风险模型,我们发现连续建模的SP-A/PL与生存时间相关(p = 0.002)。SP-A/PL高于所有IPF患者中位数水平(29.7微克/微摩尔)的患者的5年生存率是低于中位数患者的两倍多(68%对30%,p = 0.007)。除了预测的TLC百分比或多方面的临床-放射-生理评分(CRP)外,SP-A/PL在预测生存方面比大多数常规生理变量有所改善。灌洗的细胞分析不能预测该组患者的生存情况。我们得出结论,SP-A/PL是灌洗中的一种生化标志物,可预测IPF患者的生存情况。

相似文献

1
Surfactant protein A predicts survival in idiopathic pulmonary fibrosis.表面活性蛋白A可预测特发性肺纤维化患者的生存率。
Am J Respir Crit Care Med. 1995 Aug;152(2):751-9. doi: 10.1164/ajrccm.152.2.7633738.
2
Idiopathic pulmonary fibrosis. Abnormalities in the bronchoalveolar lavage content of surfactant protein A.特发性肺纤维化。支气管肺泡灌洗中表面活性蛋白A含量异常。
Am Rev Respir Dis. 1991 Jul;144(1):160-6. doi: 10.1164/ajrccm/144.1.160.
3
Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids.血清和支气管肺泡灌洗液中的肺表面活性物质蛋白D
Am J Respir Crit Care Med. 1995 Dec;152(6 Pt 1):1860-6. doi: 10.1164/ajrccm.152.6.8520747.
4
[Surfactant protein A in bronchoalveolar lavage fluid from patients with idiopathic interstitial pneumonia].特发性间质性肺炎患者支气管肺泡灌洗术中的表面活性蛋白A
Nihon Kyobu Shikkan Gakkai Zasshi. 1996 Dec;34(12):1326-30.
5
Decreased surfactant protein A in patients with bacterial pneumonia.细菌性肺炎患者中表面活性蛋白A减少。
Am Rev Respir Dis. 1993 Mar;147(3):653-7. doi: 10.1164/ajrccm/147.3.653.
6
Pneumocystis carinii alters surfactant protein A concentrations in bronchoalveolar lavage fluid.卡氏肺孢子虫可改变支气管肺泡灌洗液中表面活性蛋白A的浓度。
J Lab Clin Med. 1995 Apr;125(4):462-9.
7
Surfactant abnormalities in idiopathic pulmonary fibrosis, hypersensitivity pneumonitis and sarcoidosis.特发性肺纤维化、过敏性肺炎和结节病中的表面活性剂异常。
Eur Respir J. 1999 Sep;14(3):565-73. doi: 10.1034/j.1399-3003.1999.14c14.x.
8
Deficient hydrophilic lung surfactant proteins A and D with normal surfactant phospholipid molecular species in cystic fibrosis.囊性纤维化患者中肺表面活性物质亲水性蛋白A和D缺乏,而表面活性磷脂分子种类正常。
Am J Respir Cell Mol Biol. 1999 Jan;20(1):90-8. doi: 10.1165/ajrcmb.20.1.3253.
9
Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis.血清表面活性蛋白A和D作为特发性肺纤维化的生物标志物
Eur Respir J. 2002 Mar;19(3):439-46. doi: 10.1183/09031936.02.00081102.
10
Surfactant protein levels in severe respiratory syncytial virus infection.严重呼吸道合胞病毒感染时的表面活性物质蛋白水平
Am J Respir Crit Care Med. 1999 Apr;159(4 Pt 1):1115-8. doi: 10.1164/ajrccm.159.4.9709065.

引用本文的文献

1
Prognostic performance of Krebs von den Lungen-6, surfactant protein A, surfactant protein D levels in the serum and bronchoalveolar lavage fluid in chronic fibrosing interstitial pneumonia: a retrospective study.血清和支气管肺泡灌洗液中 Krebs von den Lungen-6、表面活性剂蛋白 A、表面活性剂蛋白 D 水平对慢性纤维化间质性肺炎的预后价值:一项回顾性研究。
BMC Pulm Med. 2024 Aug 22;24(1):404. doi: 10.1186/s12890-024-03224-1.
2
Mitochondrial DNA in bronchoalveolar lavage fluid is associated with the prognosis of idiopathic pulmonary fibrosis: a single cohort study.支气管肺泡灌洗液中的线粒体 DNA 与特发性肺纤维化的预后相关:一项单队列研究。
Respir Res. 2024 May 10;25(1):202. doi: 10.1186/s12931-024-02828-9.
3
Genetic Underpinnings of Pulmonary Fibrosis: An Overview.
遗传性肺纤维化的基础:概述。
Cardiovasc Hematol Agents Med Chem. 2024;22(3):367-374. doi: 10.2174/0118715257261006231207113809.
4
Proteomic Biomarkers of Survival in Idiopathic Pulmonary Fibrosis.特发性肺纤维化生存的蛋白质组学生物标志物。
Am J Respir Crit Care Med. 2024 May 1;209(9):1111-1120. doi: 10.1164/rccm.202301-0117OC.
5
Prostaglandin E2 (PGE2) and Roflumilast Involvement in IPF Progression.前列腺素 E2(PGE2)和罗氟司特在特发性肺纤维化进展中的作用。
Int J Mol Sci. 2023 Aug 3;24(15):12393. doi: 10.3390/ijms241512393.
6
Loss of SP-A in the Lung Exacerbates Pulmonary Fibrosis.肺中 SP-A 的缺失会加重肺纤维化。
Int J Mol Sci. 2022 May 10;23(10):5292. doi: 10.3390/ijms23105292.
7
Genetics and animal models of familial pulmonary fibrosis.家族性肺纤维化的遗传学和动物模型。
Int Immunol. 2021 Nov 25;33(12):653-657. doi: 10.1093/intimm/dxab026.
8
Role of Krebs von den Lungen-6 (KL-6) in Assessing Hypersensitivity Pneumonitis.克雷伯斯肺-6(KL-6)在评估过敏性肺炎中的作用。
Tuberc Respir Dis (Seoul). 2021 Jul;84(3):200-208. doi: 10.4046/trd.2020.0122. Epub 2021 Apr 6.
9
Genetic Risk Factors for Idiopathic Pulmonary Fibrosis: Insights into Immunopathogenesis.特发性肺纤维化的遗传风险因素:对免疫发病机制的见解
J Inflamm Res. 2021 Jan 5;13:1305-1318. doi: 10.2147/JIR.S280958. eCollection 2020.
10
Lipid Mediators Regulate Pulmonary Fibrosis: Potential Mechanisms and Signaling Pathways.脂质介质调控肺纤维化:潜在机制和信号通路。
Int J Mol Sci. 2020 Jun 15;21(12):4257. doi: 10.3390/ijms21124257.